232 filings
Page 4 of 12
8-K
1zce60vbjwcgwm ri7
17 Sep 20
Other Events
12:40pm
8-K
z2fh38 qmbo8uzq
1 Sep 20
Hepion Pharmaceuticals Completes Final Dosing in Phase 1b Multiple Ascending Dose Study of CRV431
1:27pm
8-K
xsjezd 9tu
27 Aug 20
Other Events
11:19am
8-K
78emy
12 Aug 20
Hepion Pharmaceuticals Announces Publication of Preclinical Study Evaluating CRV431’s Antiviral Properties
8:46am
8-K
y7uune wmc
5 Aug 20
Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial
9:18am
8-K
vmh2yy3c1cz1xtu64co
31 Jul 20
Submission of Matters to a Vote of Security Holders
12:00am
8-K
vof3577b1c
7 Jul 20
Hepion Pharmaceuticals Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431
8:26am
8-K
xfg301wx8p7o7e1c 9no
29 Jun 20
Hepion Pharmaceuticals Announces Advancement to Final Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
12:00am
8-K
739znjb0ot3y22qqu6n
22 Jun 20
Other Events
4:54pm
8-K
zgk ehbsf
15 Jun 20
Regulation FD Disclosure
9:22am
8-K
skg0 e8y5e
10 Jun 20
Hepion Pharmaceuticals Welcomes Industry Veteran and Drug Development Expert, Dr. Peter Wijngaard, to its Board of Directors
5:04pm
8-K
6s9j1grk ssx6
20 May 20
Hepion Pharmaceuticals Announces Advancement to Fourth Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431
4:35pm
8-K
11qrg80r06dnqan2nng
19 May 20
Regulation FD Disclosure
9:51pm
8-K
bdd6qcx5x4puhf bqx83
19 May 20
Other Events
8:12am
8-K
lx0 q9ifjg
14 May 20
Other Events
4:15pm
8-K
27xny uti0wrmgy
17 Apr 20
Entry into a Material Definitive Agreement
4:05pm
8-K
zzvatd5vg7rxa8
30 Mar 20
Other Events
4:05pm
8-K
zzbs4bwk
27 Mar 20
Other Events
12:53pm
8-K
o3g0ae
12 Mar 20
Other Events
8:47am
8-K
amoae b951rc
11 Mar 20
Regulation FD Disclosure
4:05pm